Arrhythmia severely affects the health and the lives of our human beings. There are more than 500,000 cases of sudden deaths in China every year. There have not been any new western drug products for this disease during the recent 20 years. The existing western drug products for arrhythmia are with severe side effects and they even will increase the mortality in some cases. The clinical evidence based medicine studies show that Shensong Yangxin Capsules has excellent therapeutic effects on premature beats and paroxysmal atrial fibrillation and can improve the slow rhythm of the heart. No adverse reactions of the heart are observed. Such clinical symptoms as palpitation, short of breath and insomnia can be significantly alleviated. It has won the praises from the doctors and the patients. It has become the leading brand in the treatment of arrhythmia in China.
Read this leaflet carefully, and take this medicine under the doctor or pharmacists’ direction
Generic name : Shensong Yangxin Capsules
Chinese Pinyin: Shensong Yangxin Jiaonang
[Ingredients] Ginseng, Dwarf Lilyturf Turber, Asiatic Cornelian Cherry Fruit, Danshen Root, Spine Date Seed (Stir-baked), Chinese Taxillus Herb, Red Peony Root, Ground beetle, Nardostachys Root, Golden Thread, Southern Magnoliavine Fruit, Fossilizid
[Description] Capsules containing yellowish-brown to brown granules and powder; taste, bitter.
[Functions and Indications] Replenish qi and tonify yin, activate blood and free the collateral vessels, nourish the heart to tranquilize. Indicated for ventricular premature beat (VPB) belonging to meridian obstruction syndrome with deficiency of both qi and yin, with the symptoms of palpitation, shortness of breath and hypodynamia, aggravated after moving, oppressed feelings in the precordial region, insomnia and dream disturbed sleep, night sweating, fatigue and lassitude.
[Administration and Dosage] For oral administration, 2-4 capsules once, 3 times daily.
[Adverse Reactions] Gastrectasia may emerge in individual patient.
[Precautions] This drug should combine with other medicine to the treatment of the primary disease which caused arrhythmia. Please protect from moisture after opening the moisture proof bag.
[Pharmacology and Toxicology] Preclinical & pharmacological tests showed that: This product can reduce the incidence of arrhythmia caused by CaCl2 in mice; shorten the duration of arrhythmia induced by aconitine in rats; increase the application amount of Ouabain, when making the model of the ventricular premature beat (VPB), ventricular tachycardia (VT) and ventricular fibrillation (VF) in guinea pigs. For rat myocardial ischemia-reperfusion injury model, it can reduce the severity of arrhythmia, decrease the serum levels of CK, LDH and MDA, increase the serum SOD and myocardial Na+, K+-ATP activity. It can also reduce the blood pressure, coronary artery resistance and myocardial oxygen consumption of anesthetized dogs. It can also shorten the length and reduce the weight of thrombosis of rats in vitro. [Storage] Preserve in tightly closed containers.
[Package] Aluminum-plastic package, 12 capsules/blister, 2 blister/box.
[Shelf-life] 24 months
[Executive Standard] Chinese Pharmacopoeia 2010, the 2nd supplemental volume.
[Approval No.] GYZZ Z20103032
Company name: Beijing Yiling Pharmaceutical Co., Ltd.
Manufacture address: No. 17 Tianfu street, Bio-medical base, Zhongguancun science & technology zone, Daxing district, Beijing, China.
Tel: 800 8038581 +86 10 59705130 400 8165108 400 8165109
Fax: + 86 10 59705129
Registration address: No. 19 Tianhe west road, Bio-medical base, Daxing district, Beijing, China.
Beijing Yiling Pharmaceutical Co., Ltd.